Extended versus limited pelvic lymphadenectomy during radical prostatectomy for intermediate- and high-risk prostate cancer: Early outcomes from a randomized controlled phase III study.

被引：10
|
作者：
Lestingi, Jean Felipe Prodocimo
Guglielmetti, Giuliano
Pontes, Jose, Jr.
Mitre, Anuar Ibrahim
Sarkis, Alvaro
Bastos, Diogo Assed
Riechelmann, Rachel
Mattedi, Romulo Loss
Cordeiro, Mauricio
Coelho, Rafael
Srougi, Miguel
Nahas, William Carlos
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5018
引用
收藏
页数：5
相关论文
共 50 条
  • [31] IMPACT OF EXTENT OF LYMPHADENECTOMY ON ALL CAUSE MORTALITY IN PATIENTS WITH INTERMEDIATE AND HIGH-RISK PROSTATE CANCER MANAGED WITH RADICAL PROSTATECTOMY
    Dursun, Furkan
    Elshabrawy, Ahmed
    Wang, Hanzhang
    Liss, Michael A.
    Rodriguez, Ronald
    Kaushik, Dharam
    Mansour, Ahmed M.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E988 - E988
  • [32] THE EFFECT OF NEO-ADJUVANT CHEMOTHERAPY ON RADICAL PROSTATECTOMY OUTCOMES IN INTERMEDIATE AND HIGH-RISK PROSTATE CANCER
    Kang, Taejin
    Kim, Wansuk
    Lee, Jungmin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF UROLOGY, 2010, 183 (04): : E230 - E231
  • [33] Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial
    Yang, Xinyan
    Allen, John Carson
    Aslim, Edwin Jonathan
    Tay, Kae Jack
    Yuen, Shyi Peng John
    Kanesvaran, Ravindran
    Chua, Melvin Lee Kiang
    Chong, Tsung Wen
    Ho, Sun Sien Henry
    Lee, Lui Shiong
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (11) : 1322 - 1330
  • [34] NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer
    Lui Shiong Lee
    Adelene Y. L. Sim
    Chee Wee Ong
    Xinyan Yang
    Cedric C. Y. Ng
    Wei Liu
    Vikneswari Rajasegaran
    Abner M. S. Lim
    Edwin Jonathan Aslim
    Nye-Thane Ngo
    Li-Yan Khor
    Ravindran Kanesvaran
    John Carson Jr Allen
    Kae Jack Tay
    John Shyi Peng Yuen
    Tsung Wen Chong
    Sun Sien Henry Ho
    Bin Tean Teh
    Melvin L. K. Chua
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 741 - 748
  • [35] Re: Facility-Level Variation in Pelvic Lymphadenectomy during Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2020, 204 (06): : 1381 - 1381
  • [36] Bicalutamide (150 mg) monotherapy versus LHRHa as neoadjuvant treatment in intermediate- and high-risk prostate cancer: A case matched study.
    Mitchell, Darren M.
    McDowell, Cliona
    McGivern, Ursula
    Corey, Gemma
    O'Hare, Jolyne
    O'Sullivan, Joe M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [37] Lymphadenectomy in Early-Stage Intermediate-/High-Risk Endometrioid Endometrial Cancer: Clinical Characteristics and Outcomes in an Australian Cohort
    Farrell, Rhonda
    Dixon, Suzanne C.
    Carter, Jonathan
    Webb, Penny M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (07) : 1379 - 1386
  • [38] Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials
    Nguyen, Paul L.
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2055 - 2056
  • [39] Survival Outcomes of Radical Prostatectomy Versus Radiotherapy in Intermediate-Risk Prostate Cancer: A NCDB Study
    Marsh, Sydney
    Walters, Ryan W.
    Silberstein, Peter T.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E39 - E46
  • [40] Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials
    Roach, Mack, III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3816 - 3817
12345